Newcastle University

Publications

Year: 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1984 1983 1980 1979

• Strathdee, G, Sim, A, Soutar, R, Holyoake, TL, Brown, R. HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. Carcinogenesis 2007, 28(2), 299-309.
• Smith AG, Worrillow LJ, Allan JM. A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia. Blood 2007, 109(3), 1233-1236.
• Seeberger S, Griffin RJ, Hardcastle IR, Golding BT. A new strategy for the synthesis of taurine derivatives using the 'safety-catch' principle for the protection of sulfonic acids. Organic & Biomolecular Chemistry 2007, 5(1), 132-138.
• Cheetham J, Smith DA, da Silva Dantas A, Doris KS, Patterson MJ, Bruce CR, Quinn J. A single MAPKKK regulates the Hog1 MAPK pathway in the pathogenic fungus Candida albicans. Molecular Biology of the Cell 2007, 18(11), 4603-4614.
• Cole M, Price L, Parry AP, Picton S, Waters F, Marshall S, Goran C, Parnham A, Wastell H, Reid M, Pearson ADJ, Boddy AV, Veal GJ. A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer. Pediatric Blood and Cancer 2007, 48(7), 687-695.
• Smith NR, James NH, Oakley I, Wainwright A, Copley C, Kendrew J, Womersley LM, Jürgensmeier JM, Wedge SR, Barry ST. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Molecular Cancer Therapeutics 2007, 6(8), 2198-2208.
• Veal GJ, Errington J, Tilby MJ, Pearson ADJ, Foot A, McDowell H, Ellershaw C, Pizer B, Nowell G, Pearson D, Boddy AV. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. British Journal of Cancer 2007, 96(5), 725-731.
• Logan, I., McNeill, H., Cook, S., Lu, X., Lunec, J., Robson, C.N. Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells. Prostate 2007, 67(8), 900-906.
• Conrad C, Ischenko I, Köhl G, Wiegand U, Guba M, Yezhelyev M, Ryan AJ, Barge A, Geissler EK, Wedge SR, Jauch KW, Bruns CJ. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anti-Cancer Drugs 2007, 18(5), 569-579.
• Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clinical Cancer Research 2007, 13(12), 3682-3688.
• McComb CM, Clark EL, Padget K, Harvey J, Morris NJ, Austin CA. Bioinformatic analysis of topoisomerase II binding sites. In: 30th Annual Meeting of the United Kingdom Environmental Mutagen Society. 2007, University of Cardiff, UK: Mutagenesis: Oxford University Press.
• Bell, E., Lunec, J., Tweddle, D. Cell cycle regulation targets of MYCN identified by gene expression microarrays. Cell Cycle 2007, 6(10), 1249-1256.
• López-Lázaro, M., Willmore, E., Austin, C. A. Cells lacking DNA topoisomerase IIβ are resistant to genistein. Journal of Natural Products 2007, 70(5), 763-767.
• Roberts, K., Resal, N., Edmondson, R.J. Cervical cancer in pregnancy: An assault on family and fertility. British Journal of Midwifery 2007, 15(3), 132-136.
• Clarke N, Heer R, Cheek T, Leung T, Pickard R. Changing the phenotype of urethral stroma by treatment with transforming growth factor beta-3. European Urology Supplements 2007, 6(2), 138-138.
• Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Molecular Cancer Therapeutics 2007, 6(2), 599-606.
• Ramakrishnan Y, Paleri V, Shah R, Steen IN, Wight RG, Kelly CG. Comorbidity in nasopharyngeal carcinoma: a preliminary communication on the prevalence, descriptive distribution and impact on outcome. Clinical Otolaryngology 2007, 32(6), 484-488.
• Ramakrishnan Y, Paleri V, Shah R, Steen IN, Wight RG, Kelly CG. Comorbidity in nasopharyngeal carcinoma: A preliminary communication on the prevalence, descriptive distribution and impact on outcome. Clinical Otolaryngology 2007, 32(6), 484-488.
• López-Lázaro M, Willmore E, Jobson AG, Gilroy KL, Curtis H, Padget K, Austin CA. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells. Journal of Natural Products 2007, 70(12), 1884-1888.
• Kelly C, Paleri V, Downs C, Shah R. Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer. Otolaryngology - Head and Neck Surgery 2007, 136(1), 108-111.
• Matheson EC, Hogarth LA, Case MC, Irving JAE, Hall AG. DHFR and MSH3 co-amplification in childhood acute lymphoblastic leukaemia, in vitro and in vivo. Carcinogenesis 2007, 28(6), 1341-1346.
• Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, DeSavi C, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. Journal of Medicinal Chemistry 2007, 50(9), 2213–2224.
• Lindsey JC, Lusher ME, Anderton J, Gilbertson RJ, Ellison DW, Clifford SC. Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma. British Journal of Cancer 2007, 97(2), 267-274.
• Strathdee G. Epigenetic markers and response to chemotherapy in cancer. Dis Markers 2007, 23(1-2), 43-9.
• Chinnaswamy, G., Keir, M., Cole, M., Price, L., Parry, A., Boddy, A. V., Veal, G. J. Estimating glomerular filtration rate in children with cancer - Impact of methodology on carboplatin dosing. In: 39th Annual Conference of the International Society of Paediatric Oncology. 2007, National Centre for Performing Arts, Mumbai, India: Pediatric Blood and Cancer, Wiley-Liss, Inc.
• Fielder HL, Seyfried NT, Noble M, Day AJ. Expression and functional characterization of the G1 domain from human versican. In: International Journal of Experimental Pathology: Joint British Society for Matrix Biology/Biochemical Society Focused Meeting. 2007, Sheffield Hallam University, Sheffield: Blackwell Publishing.
• Darby S, Stockley J, Khan M, Robson CN, Leung HY, Gnanapragasam VJ. Expression of GnRH type II is regulated by the androgen receptor in prostate cancer. Endocrine-Related Cancer 2007, 14(3), 613-624.
• Darby S, Stockley J, Edmonson RJ, Robson CN, Leung HY, Gnanapraga VJ. Expression of gonadotrophin releasing hormone type II in prostate cancer is androgen regulated. BJU International 2007, 99(s4), 30-30.
• Akasaka T, Balasas T, Russell LJ, Sugimoto KJ, Majid A, Walewska R, Karran EL, Brown DG, Cain K, Harder L, Gesk S, Martin-Subero JI, Atherton MG, Brüggemann M, Calasanz MJ, Davies T, Haas OA, Hagemeijer A, Kempski H, Lessard M, Lillington DM, Moore S, Nguyen-Khac F, Radford-Weiss I, Schoch C, Struski S, Talley P, Welham MJ, Worley H, Strefford JC, Harrison CJ, Siebert R, Dyer MJS. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2007, 109(8), 3451-361.
• Strefford JC, Worley H, Barber K, Wright S, Stewart ARM, Robinson HM, Bettney G, van Delft FW, Atherton MG, Davies T, Griffiths M, Hing S, Ross FM, Talley P, Saha V, Moorman AV, Harrison CJ. Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. Oncogene 2007, 26(29), 4306-4318.
• Strefford J, Worley H, Barber KJ, Wright SL, Moorman AV, Case M, Irving J, Hall A, Harrison CJ. Genomic profiling reveals multiple genetic targets in ETV6-RUNX1 positive acute lymphoblastic leukaemia (ALL). In: British Human Genetics Conference. 2007, University of York, UK: Journal of Medical Genetics: BMJ Group.
• Doshi J, Anari S, Zammit-Maempel I, Paleri V. Grisel syndrome: a delayed presentation in an asymptomatic patient. In: 42nd South African ENT Congress/British Association of Otolaryngologists Head and Neck Surgeons. 2007, Cape Town, South Africa: Journal of Laryngology and Otology, Cambridge University Press.
• Welburn JPI, Tucker JA, Johnson T, Lindert L, Morgan M, Willis A, Noble MEM, Endicott JA. How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A. Journal of Biological Chemistry 2007, 282(5), 3173-3181.
• Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, Meyer S, Eden T, Dickinson AM, Soutar R, Brown R. HOX genes are a major target for epigenetic mis-regulation in adult and childhood leukaemia. British Journal of Haematology 2007, 137, 81-81.
• Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, Meyer S, Eden T, Dickinson AM, Mountford JC, Jorgensen HG, Soutar R, Brown R. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clinical Cancer Research 2007, 13(17), 5048-5055.
• Thuwajit P, Chawengrattanachot W, Thuwajit C, Sripa B, May FEB, Westley BR, Tepsiri N, Paupairoj A, Chau-in S. Increased TFF1 trefoil protein expression in Opisthorchis viverrini-associated cholangiocarcinoma is important for invasive promotion. Hepatology Research 2007, 37(4), 295-304.
• Hardcastle IR. Inhibitors of the MDM2-p53 interaction as anticancer drugs. Drugs of the Future 2007, 32(10), 883-896.
• Robinson HM, Harrison CJ, Moorman AV, Chudoba I, Strefford JC. Intrachromosomal amplification of chromosome 21 (iAMP21) arises from a breakage-fusion-bridge cycle. Genes, Chromosomes and Cancer 2007, 46(4), 318-326.
• Cowell I, Sunter NJ, Singh PB, Austin CA, Durkacz BW, Tilby MJ. γH2AX foci form preferentially in euchromatin after ionising-radiation. PLoS ONE 2007, 2(10), e1057.
• Moorman AV, Harrison CJ, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 Trial. Blood 2007, 109(8), 3189-3197.
• Bettayeb K, Tirado OM, Marionneau-Lambot S, Ferandin Y, Lozach O, Morris JC, Mateo-Lozano S, Drueckes P, Schachtele C, Kubbutat MHG, Liger F, Marquet B, Joseph B, Echalier A, Endicott JA, Notario V, Meijer L. Meriolins, a new class of cell death-inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Research 2007, 67(17), 8325-8334.
• Paleri V, Najim O, Meikle D, Wilson JA. Microlaryngoscopic repair of iatrogenic pharyngeal pouch perforations: Treatment of choice?. Head & Neck: journal for the sciences and specialities of the head and neck 2007, 29(2), 189-192.
• Paleri V, Najim O, Meikle D, Wilson JA. Microscopic repair of iatrogenic pharyngeal pouch perforations: treatment of choice. Head and Neck 2007, 29(2), 189-192.
• Dudderidge TJ, McCracken SRC, Loddo M, Fanshawe TR, Kelly JD, Neal DE, Leung HY, Williams GH, Stoeber K. Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. British Journal of Cancer 2007, 96(9), 1384-1393.
• Wang CJ, Hagemeier C, Rahman N, Lowe E, Noble MEM, Coughtrie M, Sim E, Westwood I. Molecular cloning, characterisation and ligand-bound structure of an azoreductase from Pseudomonas aeruginosa. Journal of Molecular Biology 2007, 373(5), 1213-1228.
• Barber KE, Harrison CJ, Broadfield ZJ, Stewart ARM, Wright SL, Martineau M, Moorman AV. Molecular cytogenetic characterisation of TCF3 (E2A)/19p13 rearrangements in acute lymphoblastic leukaemia. Genes, Chromosomes and Cancer 2007, 46(5), 478-486.
• Armstrong J, Taylor GA, Thomas HD, Boddy AV, Redfern C, Veal GJ. Molecular targeting of retinoic acid metabolism in neuroblastoma: The role of the CYP26 inhibitor R116010 in vitro and in vivo. British Journal of Cancer 2007, 96(11), 1675-1683.
• Jamieson D, Wilson K, Pridgeon S, Margetts J, Edmondson R, Leung H, Knox R, Boddy AV. NAD(P)H:quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. Clinical Cancer Research 2007, 13(5), 1584-1590.
• McManamy CS, Pears J, Weston C, Hanzely Z, Ironside J, Taylor R, Grundy R, Clifford SC, Ellison DW. Nodule formation and desmoplasia in medulloblastomas - Defining the nodular/desmoplastic variant and its biological behavior. Brain Pathology 2007, 17(2), 151-164.
• Chen L, Malcolm AJ, Wood K, Cole M, Variend S, Cullinane C, Pearson ADJ, Lunec J, Tweddle DA. p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle 2007, 6(21), 2685-2696.
• Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anti-Cancer Agents in Medicinal Chemistry 2007, 7(5), 515-523.
• Lee JS, Verrill MW, Sludden J, Griffin MJ, Erb S, Sumpter KA, Cole M, Calvert AH, Boddy AV. Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer. Breast Cancer Research and Treatment 2007, 106(Supplement 1), S169 abstract 4011.
• Chinnaswamy, G., Veal, G. J., Cole, M., Taylor, G. A., Errington, J. E., Gerrard, M., Boddy, A. V. Pharmacogenetics and metabolism of cyclophosphamide in paediatric cancer patients. In: 39th Annual Conference of the International Society of Paediatric Oncology. 2007, National Centre for Performing Arts, Mumbai, India: Pediatric Blood and Cancer, Wiley-Liss, Inc.
• Veal GJ, Cole M, Errington J, Pearson ADJ, Foot A, Whyman G, Boddy AV. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - A study of the United Kingdom Children's Cancer Study Group. British Journal of Cancer 2007, 96(3), 424-431.
• Veal, G. J., Rowbotham, S., Boddy, A. V. Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma. Therapie 2007, 62(2), 91-93.
• Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. Journal of Clinical Oncology 2007, 25(29), 4603-4609.
• Higman VA, Blundell CD, Mahoney DJ, Redfield C, Noble MEM, Day AJ. Plasticity of the TSG-6 HA-binding loop and mobility in the TSG-6-HA complex revealed by NMR and X-ray crystallography. Journal of Molecular Biology 2007, 371(3), 669-684.
• Thomas HD, Calabrese CR, Batey M, Canan S, Hostomsky Z, Kyle S, Maegley K, Newell DR, Skalitzky D, Wang L, Webber SE, Curtin NJ. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Molecular Cancer Therapeutics 2007, 6(3), 945-956.
• Thomas CP, Davison Z, Heard CM. Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX. Prostaglandins, Leukotrienes and Essential Fatty Acids 2007, 76(6), 357-362.
• Moorman AV, Richards SM, Robinson HM, Strefford JC, Gibson BES, Kinsey SE, Eden TOB, Vora AJ, Mitchell CD, Harrison CJ. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 2007, 109(6), 2327-2330.
• Hollick J, Rigoreau L, Cano-Soumillac C, Cockcroft X, Curtin NJ, Frigerio M, Golding BT, Guiard S, Hardcastle IR, Hickson I, Hummersone M, Menear K, Martin N, Matthews I, Newell DR, Ord R, Richardson C, Smith G, Griffin RJ. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase. Journal of Medicinal Chemistry 2007, 50(8), 1958-1972.
• Routledge DM, Jackson A, Bourn D, Bown NP, Cole M, Slatter MA, Gennery AR, Curtis A. Quantitative assessment of mixed chimerism in allogeneic stem cell transplant patients - A comparison of molecular genetic and cytogenetic approaches. Journal of Pediatric Hematology / Oncology 2007, 29(6), 428-431.
• Barbeau OR, Cano-Soumillac C, Griffin RJ, Hardcastle IR, Smith GCM, Richardson C, Clegg W, Harrington RW, Golding BT. Quinolinone and pyridopyrimidinone inhibitors of DNA-dependent protein kinase. Organic & Biomolecular Chemistry 2007, 5(16), 2670-2677.
• Williamson D, Selfe J, Gordon T, Lu YJ, Pritchard-Jones K, Murai K, Jones P, Workman P, Shipley J. Role for amplification and expression of Glypican-5 in rhabdomyosarcoma. Cancer Research 2007, 67(1), 57-65.
• Armstrong, J.L., Veal, G.J., Redfern, C.P.F., Lovat, P.E. Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours. Apoptosis 2007, 12(3), 613-622.
• Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. Journal of Pathology 2007, 213(1), 82-90.
• Seedhouse CH, Grundy M, White P, Li Y, Fisher J, Yakunina D, Moorman AV, Hoy T, Russell N, Burnett A, Pallis M. Sequential influences of leukaemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukaemia 14 and 15 trials. Clinical Cancer Research 2007, 13(23), 7059-7066.
• Trempe JF, Endicott JA. Structural biology - Pass the protein. Nature 2007, 445(7126), 375-376.
• Marchetti F, Sayle KL, Bentley J, Clegg W, Curtin NJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Harrington RW, Mesguiche V, Newell DR, Noble MEM, Parsons RJ, Pratt DJ, Wang L, Hardcastle IR, Mesguiche V, Newell DR, Noble MEM, Parsons RJ, Pratt DJ, Wang L, Hardcastle IR. Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinase 2. Organic and Biomolecular Chemistry 2007, 5(10), 1577-1585.
• Banerji S, Wright AJ, Noble M, Mahoney DJ, Campbell ID, Day AJ, Jackson DG. Structures of the Cd44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction. Nature Structural & Molecular Biology 2007, 14(3), 234-239.
• Pastok MW, Murray PA, Dart C, Rees HH, Fisher MJ. Studies on the C. elegans Protein Kinase A (PK-A) Catalytic and Regulatory Subunit Genes. In: International Worm Meeting (2007). 2007, UCLA.
• Galaal K, Meirovitz M, Hussain R, Allcroft L, Sullivan N, Lopes AD, Edmondson RJ. The feasibility of storing ovarian tumor cells on databasing paper: establishing a library of ovarian cancer DNA. International Journal of Gynecological Cancer 2007, 17(1), 94-100.
• Heer, R., Robson, C. N., Shenton, B. K., Leung, H. Y. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population. Journal of Cellular Physiology 2007, 212(3), 572-578.
• Rigas AC, Robson CN, Curtin NJ. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene 2007, 26(55), 7611-7619.
• Curtin NJ. Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opinion on Therapeutic Targets 2007, 11(6), 783-799.
• Bomken, S.N., Davies, B., Chong, L.A., Wood, K., McDermott, M., Tweddle, D.A. Tumour necrosis following chemotherapy in neuroblastoma correlates with MYC-N status but not survival. Pediatric Blood & Cancer 2007, 49(4), 517-517.
• Strefford JC, An Q, Wright SL, Konn ZJ, Matherson E, Minto L, Moorman AV, Parker H, Hall A, Irving J, Harrison CJ. Variable Breakpoints Target PAX5 in Patients with Dicentric Chromosomes: A Model for the Basis of Unbalanced Translocations in Cancer. In: 49th Annual Meeting of the American Society of Hematology. 2007, Atlanta, Georgia: Blood: American Society of Hematology.